Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia

Matthew F. Pullen; Francis Kakooza; Elizabeth Nalintya; Agnes N. Kiragga; Bozena M. Morawski; Radha Rajasingham; Anthony Mubiru; Yukari C. Manabe; Jonathan E. Kaplan; David B. Meya; David R. Boulware

doi:10.1093/cid/ciz418

Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia

Matthew F. Pullen, Francis Kakooza, Elizabeth Nalintya, Agnes N. Kiragga, Bozena M. Morawski, Radha Rajasingham, Anthony Mubiru, Yukari C. Manabe, Jonathan E. Kaplan, David B. Meya, David R. Boulware

School of Medicine

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	353-355
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	70
Issue number	2
DOIs	https://doi.org/10.1093/cid/ciz418
State	Published - Jan 15 2020

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciz418

Cite this

Pullen, M. F., Kakooza, F., Nalintya, E., Kiragga, A. N., Morawski, B. M., Rajasingham, R., Mubiru, A., Manabe, Y. C., Kaplan, J. E., Meya, D. B., & Boulware, D. R. (2020). Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia. Clinical Infectious Diseases, 70(2), 353-355. https://doi.org/10.1093/cid/ciz418

Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia. / Pullen, Matthew F.; Kakooza, Francis; Nalintya, Elizabeth et al.

In: Clinical Infectious Diseases, Vol. 70, No. 2, 15.01.2020, p. 353-355.

Research output: Contribution to journal › Letter › peer-review

Pullen, MF, Kakooza, F, Nalintya, E, Kiragga, AN, Morawski, BM, Rajasingham, R, Mubiru, A, Manabe, YC, Kaplan, JE, Meya, DB & Boulware, DR 2020, 'Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia', Clinical Infectious Diseases, vol. 70, no. 2, pp. 353-355. https://doi.org/10.1093/cid/ciz418

@article{70425f95a95b443892ebd170219abb41,

title = "Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia",

author = "Pullen, {Matthew F.} and Francis Kakooza and Elizabeth Nalintya and Kiragga, {Agnes N.} and Morawski, {Bozena M.} and Radha Rajasingham and Anthony Mubiru and Manabe, {Yukari C.} and Kaplan, {Jonathan E.} and Meya, {David B.} and Boulware, {David R.}",

note = "Funding Information: Financial support. This work was supported by the President{\textquoteright}s Emergency Plan for AIDS Relief (PEPFAR) though the Centers for Disease Control and Prevention (grant number U01GH000517). Funding Information: Potential conflicts of interest. M. F. P., D. R. B., D. B. M., E. N., and R. R. have received grant support from the National Institute of Allergy and Infectious Diseases. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.",

year = "2020",

month = jan,

day = "15",

doi = "10.1093/cid/ciz418",

language = "English (US)",

volume = "70",

pages = "353--355",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia

AU - Pullen, Matthew F.

AU - Kakooza, Francis

AU - Nalintya, Elizabeth

AU - Kiragga, Agnes N.

AU - Morawski, Bozena M.

AU - Rajasingham, Radha

AU - Mubiru, Anthony

AU - Manabe, Yukari C.

AU - Kaplan, Jonathan E.

AU - Meya, David B.

AU - Boulware, David R.

N1 - Funding Information: Financial support. This work was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) though the Centers for Disease Control and Prevention (grant number U01GH000517). Funding Information: Potential conflicts of interest. M. F. P., D. R. B., D. B. M., E. N., and R. R. have received grant support from the National Institute of Allergy and Infectious Diseases. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

PY - 2020/1/15

Y1 - 2020/1/15

UR - http://www.scopus.com/inward/record.url?scp=85077404469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077404469&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz418

DO - 10.1093/cid/ciz418

M3 - Letter

C2 - 31119280

AN - SCOPUS:85077404469

SN - 1058-4838

VL - 70

SP - 353

EP - 355

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this